Key takeaway
DOZA works only with products whose efficacy is proven in clinical trials. Key data: SURMOUNT-1 (tirzepatide, -22.5%), STEP-1 (semaglutide, -14.9%), TRIUMPH-1 (retatrutide, -28.3%, topline Phase 3). All sources are peer-reviewed publications in NEJM and The Lancet.
Clinical trials, comparison table of 6 GLP-1 products, official FDA instructions and warnings about dangerous analogs
Quick comparison of key indicators
Tirzepatide
Semaglutide
Semaglutide
Liraglutide
Tirzepatide
Semaglutide (oral)
HbA1cGlycated hemoglobin — an indicator of average blood sugar levels over the past 2-3 months. Normal: 4-5.6% Reduction
-1.5% to -1.8%
vs. placebo
Weight Loss
6-7 kg
SUSTAIN, 1-2 mg doses; -14.9% only at 2.4 mg (STEP-1)
Cardiovascular Safety
-26%
event risk (SUSTAIN 6)
Adaptation features (≥5% of participants):
FDA Warning
Pancreatitis, thyroid tumors (C-cell, in rodents), acute kidney injury, intestinal obstruction, vision changes, hypoglycemia when combined with insulin.
HbA1cGlycated hemoglobin — an indicator of average blood sugar levels over the past 2-3 months. Normal: 4-5.6% Reduction
-1.9% to -2.46%
SURPASS-1..5, efficacy estimand
Weight Loss
up to 22.5% (~24 kg)
SURMOUNT-1, 72 weeks, 15 mg
SURPASS-2 vs semaglutide 1 mg
-12.4 kg
-2.46% HbA1cGlycated hemoglobin — an indicator of average blood sugar levels over the past 2-3 months. Normal: 4-5.6% (15 mg, efficacy estimand) vs -1.86% semaglutide
Adaptation features (≥5% of participants):
BLACK BOX WARNING (FDA)
Thyroid C-cell tumors: Tirzepatide causes thyroid tumors in rats. It is unknown whether this applies to humans.
Weight Loss
-16.9% (~17 kg)
STEP-1, 68 weeks, 2.4 mg (trial product estimand — completers)
Cardioprotection
-20% MACE
SELECT trial, 17,604 participants
vs Placebo
-12.4% difference
STEP-1 (plc: -2.4%)
Adaptation features (≥5% of participants):
FDA Warning (Black Box)
Risk of medullary thyroid carcinoma (C-cell tumors in rodents). Contraindicated in MEN 2 or family history of medullary thyroid carcinoma.
Weight Loss
-8% (~8 kg)
SCALE, 56 weeks, 3 mg
Response ≥5%
63.2% of patients
vs 27.1% placebo
Market Experience
10+ years
One of the most studied GLP-1s
Adaptation features (≥5% of participants):
FDA Warning (Black Box)
Risk of medullary thyroid carcinoma (C-cell tumors in rodents). Contraindicated in MEN 2. Daily administration — less convenient compared to weekly injections.
Weight Loss
-22.5% (~24 kg)
SURMOUNT-1, 72 weeks, 15 mg
Response ≥20%
36.2% of patients
vs 1.5% placebo
Sleep Apnea
FDA Dec 2024
Approved for obstructive sleep apnea
Adaptation features (≥5% of participants):
ℹ️ Note
Zepbound = same molecule (tirzepatide) as Mounjaro. Mounjaro is registered for type 2 diabetes (FDA 2022), Zepbound — for chronic weight management (FDA 2023). Also approved for sleep apnea (FDA Dec 2024).
HbA1cGlycated hemoglobin — an indicator of average blood sugar levels over the past 2-3 months. Normal: 4-5.6% Reduction
-1.0% to -1.4%
PIONEER 1-10
Weight Loss
-2.6 kg vs placebo
PIONEER-1, 26 weeks, 14 mg (trial product estimand)
Uniqueness
First oral GLP-1
The only GLP-1 in tablet form
Adaptation features (≥5% of participants):
ℹ️ Note
Rybelsus is the only GLP-1 agonist in tablet form. Less effective for weight loss than injectable Wegovy (semaglutide 2.4 mg), but more convenient for patients who prefer to avoid injections. Take on an empty stomach 30 min before food with ≤120 ml water.
Weight Loss
-22.7%
REDEFINE-1, 68 weeks
vs Wegovy
~6% advantage
CagriSema vs semaglutide 2.4 mg alone
New Mechanism
Amylin + GLP-1
First amylin analog for obesity
Adaptation features (≥5% of participants):
ℹ️ Note
CagriSema = combination of cagrilintide (amylin analog) + semaglutide (GLP-1). Not yet approved. NDA filed with the FDA on 18 Dec 2025; decision expected Q4 2026. May become a competitor to Zepbound/Mounjaro by Eli Lilly.
Weight Loss
-28.3% (~31.9 kg)
TRIUMPH-1 (Phase 3, topline 2026), 80 weeks, 12 mg
Triple Mechanism
GLP-1 + GIP + GCG
First triple agonist
BLA submission (FDA)
Q1 2027
Highest result in the GLP-1 class (topline)
Adaptation features (≥5% of participants):
ℹ️ Note
Retatrutide is not yet approved by any regulator. The -28.3% result is topline Phase 3 TRIUMPH-1 data (2026); the full peer-reviewed publication is pending. BLA submission to the FDA is planned for Q1 2027.
Trust Rating
2 / 5
No proprietary clinical data
Proprietary Clinical Trials
None
References SURMOUNT-1 (Eli Lilly)
Composition Verification
Not confirmed
No independent analysis published
Side Effects:
🚨 IMPORTANT WARNING
Biopatid is manufactured by UNIKKA PHARMA (Brazil), not Eli Lilly — the developer of the tirzepatide molecule. Eli Lilly officially states it does not supply tirzepatide to any third-party manufacturers. Biopatid has not undergone its own clinical trials. The API is imported not from Eli Lilly. Not listed in Ukraine's State Register of Medicines (drlz.com.ua). Consult your doctor.
Trust Rating
1 / 5
No registration, no clinical data
Own Clinical Trials
None
No published RCTs
Cold Chain
Not Verified
Route from Dhaka to Ukraine is opaque
Side Effects:
🚨 CRITICAL WARNING
TIRZEMA is made by Incepta Pharmaceuticals (Bangladesh), NOT Eli Lilly. Even in Bangladesh itself, the DGDA has not issued final marketing authorization — the Drug Control Committee has not convened for nearly 2 years. Only doses up to 7.5 mg are available — the target 10–15 mg (SURMOUNT-1: −22.5% weight loss) cannot be reached. The WTO LDC patent waiver for Bangladesh expires November 2026. The delivery route to Ukraine is opaque, and cold chain (2–8°C) is not verified. Reuters (2024) documented seizures of similar Incepta copies by UK, Swiss, and Irish customs.
All key characteristics in one table
| Characteristic | Mounjaro | Ozempic | Wegovy | Saxenda | Zepbound | Rybelsus | Retatrutide | Biopatid | Cagrilintide | TIRZEMA |
|---|---|---|---|---|---|---|---|---|---|---|
| Status | Approved | Approved | Approved | Approved | Approved | Approved | Phase 3 | Not Approved | Phase 3 | Not Approved |
| Active Ingredient | Tirzepatide | Semaglutide | Semaglutide | Liraglutide | Tirzepatide | Semaglutide (oral) | LY3437943 | Tirzepatide (as claimed by manufacturer) | Cagrilintide (amylin analog) | Tirzepatide (claimed, Incepta Pharmaceuticals) |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk | Novo Nordisk | Eli Lilly | Novo Nordisk | Eli Lilly | UNIKKA PHARMA (LCA Farmacêutica LTDA), Brazil · distribution by Biopell Medical | Novo Nordisk | Incepta Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Mechanism of Action | GLP-1 + GIP (dual) | GLP-1 only | GLP-1 only | GLP-1 only | GLP-1 + GIP (dual) | GLP-1 only | GLP-1 + GIP + Glucagon (triple) | GLP-1+GIP (as claimed — same molecule as Mounjaro) | Amylin analog (+ semaglutide in CagriSema) | GLP-1+GIP (claimed same molecule as Mounjaro) |
| Average Weight Loss | -22.5% | -14.9% | -16.9% | -8% | -22.5% | -2.6 kg vs placebo | -28.3% | — | -22.7% (CagriSema) | — |
| ~in kilograms | ~24 kg | ~15 kg | ~17 kg | ~8 kg | ~24 kg | ~2.6 kg (vs placebo) | ~32 kg | — | ~23 kg | — |
| Dosing Frequency | Once weekly | Once weekly | Once weekly | Daily | Once weekly | Daily (tablet) | Once weekly | 1× per week (per manufacturer's instructions) | Once weekly | Once/week (per manufacturer) |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.25, 0.5, 1, 2 mg | 0.25, 0.5, 1, 1.7, 2.4 mg | 0.6, 1.2, 1.8, 2.4, 3 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg | 3, 7, 14 mg | In development | Vials 40/60 mg | In development | Only 2.5, 5, 7.5 mg |
| Side Effects | Adaptation period: nausea (25-33%), diarrhea (19-23%) — SURMOUNT-1 | Adaptation period: nausea, vomiting (15-20%, SUSTAIN) | Adaptation period: nausea (44%), vomiting (25%) — STEP-1 | Adaptation period: nausea (up to 40%) — SCALE | Adaptation period: nausea (25-33%), diarrhea (19-23%) — SURMOUNT-1 | Nausea (in 15-20%), diarrhea | Limited data (Phase 2-3) | No proprietary clinical data available | Nausea, diarrhea (Phase 3 data) | No proprietary clinical data |
| FDA Approval | FDA 2022 | FDA 2017 | FDA 2021 | FDA 2014 | FDA 2023 | FDA 2019 | Phase 3 (expected 2026–2028) | Not approved by FDA/EMA/ANVISA as a standalone product | Phase 3 (CagriSema — expected 2026) | Not registered by any regulator |
| References | Phase 2No instructions available | No proprietary RCTs conductedNo instructions available | REDEFINE-1No instructions available | No proprietary RCTs conductedNo instructions available |
Every DOZA claim is backed by a specific clinical study with a defined evidence level
| Claim | Source | Evidence Level | Notes |
|---|---|---|---|
| Tirzepatide: −22.5% body weight | SURMOUNT-1 | Level I — RCT | n=2539, 72 wk |
| Semaglutide: −14.9% body weight | STEP-1 | Level I — RCT | n=1961, 68 wk |
| Tirzepatide outperforms semaglutide on HbA1cGlycated hemoglobin — an indicator of average blood sugar levels over the past 2-3 months. Normal: 4-5.6% | SURPASS-2 | Level I — RCT | n=1879, 40 wk |
| Semaglutide: −20% cardiovascular events (MACE) | SELECT | Level I — RCT | n=17604, ~40 mo |
| CagriSema: −22.7% body weight | REDEFINE-1 | Level I — RCT | n=3417, 68 wk |
| Retatrutide: −28.3% body weight | Phase 3 TRIUMPH-1 (topline 2026) | Level I — RCT (topline, pre-publication) | n=2339, 80 wk |
| Retatrutide: −24.2% body weight | Phase 2 (NEJM) | Level II — Phase 2/3 | n=338, 48 wk |
| Liraglutide: −8% body weight | SCALE | Level I — RCT | n=3731, 56 wk |
Evidence levels per Oxford CEBM 2011. Level I — large-scale randomized controlled trials. Level II — Phase 2-3 trials with limited samples. Level IV — real-world practice data, not peer-reviewed.
How we collect and process anonymized client outcomes
DOZA collects anonymized data on weight loss, adherence, and side effects from real-world practice. This data is NOT a clinical trial — it lacks a control group, has not been peer-reviewed, and has a limited sample size.
~1,200 clients (2024–2026)
Client self-reports + CRM data
No control group, possible self-selection bias
Products that have NOT yet received full FDA/EMA regulatory approval
These products are still undergoing clinical trials. Results may change. DOZA offers them with full status disclosure.
LY3437943 — Triple GLP-1 + GIP + Glucagon
What we know for sure — and where data gaps exist
Most RCTs last 52–72 weeks. Data beyond 2 years is limited. Post-discontinuation effects remain understudied.
DOZA internal data comes from motivated, financially capable clients — this is not a representative sample of the general population.
Retatrutide and cagrilintide are not yet FDA/EMA approved. Phase 2/3 results may not be confirmed in pivotal trials.
Clinical trial results are averages. Individual response to GLP-1 therapy varies significantly (from -5% to -30% weight loss).
DOZA commits to updating this page as new data becomes available. Last updated: August 2026.
Based on clinical evidence
Mounjaro is the only product that targets both GLP-1 and GIP receptors simultaneously. This provides better appetite control and higher efficacy.
In SURMOUNT-1, participants lost an average of 22.5% of body weight over 72 weeks — 7.6 percentage points more than in the STEP 1 trial (semaglutide, -14.9%).
Lower nausea rates in SURMOUNT-1 (25-33% at 5-15 mg) compared with STEP-1 for semaglutide 2.4 mg (44%).
Studies show that Mounjaro users lose more fat and less muscle mass.
Links to original scientific publications
Mounjaro (Tirzepatide) • 2539 participants • 72 weeks
Mounjaro (Tirzepatide) • 938 participants • 72 weeks
Tirzepatide vs Semaglutide • 1879 participants • 40 weeks
Wegovy / Semaglutide • 1961 participants • 68 weeks
Semaglutide • 1210 participants • 68 weeks
Saxenda (Liraglutide) • 3731 participants • 56 weeks
Wegovy (Semaglutide 2.4 mg) • 17604 participants • ~40 months
Rybelsus (Oral Semaglutide) • 703 participants • 26 weeks
CagriSema (Cagrilintide + Semaglutide) • 3417 participants • 68 weeks
All links lead to official publications in PubMed and NEJM. We recommend reviewing them before starting a program.
FDA-approved documents
New England Journal of Medicine • 2022
The SURMOUNT-1 study showed that participants taking 15 mg tirzepatide lost an average of 22.5% body weight over 72 weeks (efficacy estimand; ITT analysis — 20.9%). This is one of the highest results among studied weight loss products.
Read studyNew England Journal of Medicine • 2021
Head-to-head comparison of tirzepatide with semaglutide (Ozempic). Tirzepatide showed superiority in HbA1cGlycated hemoglobin — an indicator of average blood sugar levels over the past 2-3 months. Normal: 4-5.6% and body weight reduction compared to 1 mg semaglutide.
Read studyCurrent Pharmaceutical Design • 2011
A review of BPC-157 research — a peptide with potent regenerative properties. Efficacy demonstrated for ulcers, inflammatory bowel diseases, and wound healing.
Read studyEuropean Journal of Endocrinology • 1998
Research shows that ipamorelin is the first selective growth hormone secretagogue that does not affect cortisol and prolactin levels, making it a safer option.
Read studyScience • 2015
A review of the role of NAD+ in metabolism and aging. Studies show that increasing NAD+ levels may improve mitochondrial function and slow aging processes.
Read studyDOZA specialist answers based on clinical trial data
Based on clinical trial data, tirzepatide (Mounjaro/Zepbound) demonstrates the highest efficacy among approved drugs — -22.5% body weight over 72 weeks (SURMOUNT-1, NEJM 2022). Retatrutide — a triple GLP-1/GIP/glucagon agonist — showed -28.3% over 80 weeks in Phase 3 TRIUMPH-1 (topline 2026; Phase 2 result was -24.2%, Jastreboff, NEJM 2023), but is not yet FDA-approved.
Valentyna Tytorenko
Diploma-certified endocrinologist, certified dietitian and nutritionist
Our specialist will help you choose the optimal product, dosage, and body sculpting program for you
Buy Mounjaro in Ukraine
Original Eli Lilly KwikPen — with personal DOZA support
In 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
Take the testIn 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
Take the test
